EFFECTS OF MEDROXYPROGESTERONE ACETATE THERAPY ON ADVANCED OR RECURRENT BREAST-CANCER AND ITS INFLUENCES ON BLOOD-COAGULATION AND THE FIBRINOLYTIC SYSTEM

被引：10

作者：

ABE, O

ASAISHI, K

IZUO, M

ENOMOTO, K

KOYAMA, H

TOMINAGA, T

NOMURA, Y

OHSHIMA, A

AOKI, N

TSUKADA, T

机构：

[1] Department of Surgery, School of Medicine, Keio University

[2] First Department of Surgery, Sapporo Medical College

[3] Second Department of Surgery, School of Medicine, Gunma University

[4] Department of Surgery, School of Medicine, Keio University

[5] Department of Surgery, The Center for Adult Diseases, Osaka

[6] Department of Surgery, Tokyo Metropolitan Komagome Hospital

[7] Department of Breast Surgery, National Kyushu Cancer Center Hospital

[8] Department of Cancer Prevention, Osaka Cancer Prevention and Detection Center

[9] First Department of Internal Medicine, Tokyo Medical and Dental University School of Medicine

[10] Department of Hematology, Toranomon Hospital

来源：

SURGERY TODAY-THE JAPANESE JOURNAL OF SURGERY | 1995年 / 25卷 / 08期

关键词：

MEDROXYPROGESTERONE ACETATE (MPA); ADVANCED OR RECURRENT BREAST CANCER; BLOOD COAGULATION; FIBRINOLYTIC SYSTEM;

D O I：

10.1007/BF00311486

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

The effects of medroxyprogesterone acetate (MPA) therapy on advanced or recurrent breast cancer and its influence on blood coagulation and the fibrinolytic system were compared among three different therapy regimens consisting of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) + MPA and CAF or MPA alone, A clinical response was observed in 42.9% (9/21) of the patients for CAF + MPA, 36.4% (8/22) for CAF and 23.8% (5/21) for MPA alone, No marked thrombosis or its prodromal condition was observed in any group, The effects on the test values for blood coagulation and the fibrinolytic system did not significantly change in the CAF group, However, both AT-III and protein C significantly increased above the normal ranges in the CAF + MPA and MPA groups, Increases in factor X, plasminogen, and alpha(2)-plasmin inhibitor/plasmin complex (PIG) and decreases in fibrinogen, tissue plasminogen activator, and D-dimer, were all observed in the MPA and CAF + MPA groups, especially in the MPA group, although these changes remained within the normal ranges, The data indicated that MPA has various influences on blood coagulation and the fibrinolytic system, but these changes did not suggest activation of the blood coagulation system.

引用

页码：701 / 710

页数：10

共 18 条

[1] Standards for assessment of the therapeutic effects in advanced or recurrent breast cancer patients, General rules for clinical and pathological recording of breast cancer, pp. 53-61, (1992)
[2] Criteria for the evaluation of the clinical effects of solid cancer chemotherapy, Nippon Gann Chiryou Gakkaishi (J Jpn Soc Cancer Ther), 21, pp. 931-942, (1986)
[3] Tominaga T., Izuo M., Nomura Y., Kubo K., Abe O., Enomoto K., Takatani O., Oral high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer: A dose response evaluartion, Gan To Kagakuryoho (Jpn J Cancer Chemother), 9, pp. 1994-2004, (1982)
[4] Yoshida M., Murai H., Miura S., Therapeutic effects of medroxyprogresterone acetate in recurrent or advanced breast cancer, Gan To Kagakuryoho (Jpn J Cancer Chemother), 12, pp. 516-523, (1985)
[5] Tominaga T., Abe O., Ohshima A., Hayasaka H., Uchino J., Abe R., Enomoto K., Izuo M., Watanabe H., Takatani O., Yoshida M., Sakai K., Koyama H., Hattori T., Senoo T., Monden Y., Nomura Y., Comparison of chemotherapy with or without medroxyprogesterone acctate for advanced or recurrent breast cancer, Eur J Cancer, 30 A, pp. 959-964, (1994)
[6] Lober J., Mouridsen H.T., Rose C., Oral or intramuscular treatment of advanced breast cancer with medroxyprogesterone acetate: A review, Role of medroxyprogesterone in endocrine-related tumors, vol. 2, pp. 105-114, (1983)
[7] Robustelli Della Cuna G., Pellegrini A., Medroxyprogesterone acetate in combination with chemotherapy for advanced breast cancer: Update results and criticisms, Role of medroxyprogesterone in endocrine-related tumors, vol. 3, pp. 91-104, (1984)
[8] Occurrence of thrombosis during the administration of high-dose medroxyprogesterone acetate in patients with breast cancer and endometrial cancer, Iyakuhin Kenkyu, 23, 5, pp. 664-671, (1992)
[9] Bonsignori M., Rossi G., Sturba F., Cajozzo A., Abbadessa V., DeSandre G., Bassetto M.A., Benini F., Bonetti A., Capelli M.C., Falezza G.C., Franccschi T., Molino A., Gibelli A., Rocchini G.M., Luporini G., Beretta G., Fraschini P., Tabiadon D., Gambrosier P., Malacarne P., Bertusi M., Indelli M., Rausa L., Palmeri S., Robustelli Della Cuna G., Bernardo A., Bernardo G., Schieppati G., Navassa G., Battaglia A., Militello S., Perbellini A., Pollini C., Sacchetti G., Sani V., Soldati M., Protectiv
[10] Effects of chemoendocrine therapy on the coagulation-fibrinolytic systems in patients with advanced breast cancer, Jpn J Cancer Res, 84, pp. 455-461, (1993)

← 1 2 →